Recommended Conferences

Cancer-Treatment and Therapeutics

New York, USA
Related Subjects

Effects of chenodeoxycholate and a bile acid sequestrant, colesevelam, on intestinal transit and bowel function

Author(s): Odunsi-Shiyanbade ST, Camilleri M, McKinzie S, Burton D, Carlson P, Busciglio IP, et al


Background & Aims Di-α hydroxy bile salt, sodium chenodeoxycholate (CDC), and bile acid binding have unclear effects on colonic transit in health and disease. Methods We performed 2 randomized, double-blind, placebo-controlled studies. In healthy volunteers (20 per group), we evaluated the effects of oral placebo, 500 mg, or 1000 mg of CDC (delayed-release, each given for 4 days) on gastrointestinal and colonic transit. A second trial compared the effects of colesevelam (1.875 g, twice daily) versus placebo in 24 patients (12 per group) with diarrhea-predominant irritable bowel syndrome (IBS-D) on transit, daily bowel frequency and consistency, and colonic mucosal permeability. Serum fasting 7α-hydroxy-4-cholesten-3-one (7αC4) was measured to screen for bile acid malabsorption. Effects of treatments on transit were compared using analysis of covariance with body mass index and 7αC4 as covariates. Results In healthy volunteers, CDC significantly accelerated colonic transit (at 24 and 48 hours, P = .01 and P < .0001, respectively), increased stool frequency and ease of passage (both P < .001), and evacuation (P = .02), and decreased stool consistency (P < .001). Four of the 24 IBS-D patients had increased serum 7αC4 levels. In IBS-D, colesevelam modestly affected overall colonic transit (24 h; P = .22). Emptying of the ascending colon took an average of 4 hours longer in patients given colesevelam compared with placebo; treatment effect was associated with baseline serum 7αC4 levels (P = .0025). Colesevelam was associated with greater ease of stool passage (P = .048) and somewhat firmer stool consistency (P = .12). No effects on mucosal permeability or safety were identified. Conclusions Sodium chenodeoxycholate in health and colesevelam in IBS-D patients have opposite effects on colonic transit and fecal parameters.

Similar Articles

Gut microbiota role in dietary protein metabolism and health-related outcomes: The two sides of the coin

Author(s): Portune KJ, Beaumont M, Davila AM, Tomé D, Blachier F, Sanz Y

Deoxycholic and chenodeoxycholic bile acids induce apoptosis via oxidative stress in human colon adenocarcinoma cells

Author(s): Ignacio BJ, Olmo N, Perez-Ramos P, Santiago-Gómez A, Lecona E, Turnay J, et al

Intestinal bile acid physiology and pathophysiology

Author(s): Martínez-Augustin O, Sánchez de Medina F

Dose-dependent antiinflammatory effect of ursodeoxycholic acid in experimental colitis

Author(s): Martínez-Moya P, Romero-Calvo I, Requena P, Hernández-Chirlaque C, Aranda CJ, González R, et al

Effect of ursodeoxycholic acid on bile acid profiles and intestinal detoxification machinery in primary biliary cirrhosis and health

Author(s): Dilger K, Hohenester S, Winkler-Budenhofer U, Bastiaansen BAJ, Schaap FG, Rust C, et al

Bile acids as carcinogens in human gastrointestinal cancers

Author(s): Bernstein H, Bernstein C, Payne CM, Dvorakova K, Garewal H

Bile acids regulate intestinal cell proliferation by modulating EGFR and FXR signaling

Author(s): Dossa AY, Escobar O, Golden J, Frey MR, Ford HF, Gayer CP

A regulatory cascade of the nuclear receptors FXR, SHP-1, and LRH-1 represses bile acid biosynthesis

Author(s): Goodwin B, Jones SA, Price RR, Watson MA, McKee DD, Moore LB, et al

Increase in fecal primary bile acids and dysbiosis in patients with diarrhea-predominant irritable bowel syndrome

Author(s): Duboc H, Rainteau D, Rajca S, Humbert L, Farabos D, Maubert M, et al

Connecting dysbiosis, bile-acid dysmetabolism and gut inflammation in inflammatory bowel diseases

Author(s): Duboc H, Rajca S, Rainteau D, Benarous D, Maubert MA, Quervain E, et al